Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corynan is an alkaloid isolated from *Petasites hybridus* (butterbur) that is being investigated for its antitumor and anti-migratory properties. Preclinical studies, primarily conducted by researchers at the National Medical Research Centre for Oncology in Russia, have demonstrated that corynan can induce apoptosis in HeLa cervical cancer cells by increasing the BAX/BCL-2 expression ratio. Furthermore, it has shown potent anti-migratory effects in A431 skin cancer cells, significantly reducing cell motility in wound healing assays. As a plant-derived secondary metabolite, corynan represents a potential lead compound for the development of new cancer therapies targeting cell survival and metastatic potential.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corynan.